10x Genomics (TXG)
(Delayed Data from NSDQ)
$37.53 USD
+0.64 (1.73%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $37.52 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
TXG 37.53 +0.64(1.73%)
Will TXG be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TXG
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Other News for TXG
Scotiabank Sticks to Its Hold Rating for Torex Gold Resources (TORXF)
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
Torex Gold Expands Reserves, Eyes Sustained Production
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
Cathie Wood's ARK Investment bought 241K shares of 10x Genomics today